RxDoctor Payments Data

Vani Manchanda, DPM

Primary Podiatric Medicine · New York, NYNPI 1154818979

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $350 of the $403 with a category attached, or 86.8%. 8 manufacturers reported payments, led by Organogenesis Inc. at 42.9% of the total. Reporting peaked in 2019 at $207 and has fallen 83.8% since, to $33 in 2024. That places this record below the midpoint for primary podiatric medicine clinicians in NY, where the typical reported total is $383.

$403in general payments, 2019–2025

Across 16 payments — averaging $25.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Organogenesis Inc.$173
  • Paratek Pharmaceuticals, Inc.$78
  • Orthofix Medical, Inc.$34
  • AbbVie$30
  • Smith+Nephew$29
  • Sebela Pharmaceuticals Inc.$25
  • plus $34 from 2 others

What the payments were for

  • Speaking & faculty fees$5313%
  • Food & beverage$35087%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$403 in reported general payments places this provider in the 50th percentile of 85 primary podiatric medicine providers in New York.

See all primary podiatric medicine providers in New York

Medicare billing

Part B allowed, 2024
$38,291
Medicare patients
214
Services billed
611

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ciclopirox12$604
CiclopiroxCiclopirox Olamine14$268
Ketoconazole12$264
Ammonium Lactate12$173
Methylprednisolone11$62
Cephalexin13$38
Meloxicam14$19

Paid to pharmacies, not to this prescriber.

Other primary podiatric medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →